C3I | Jotup

C3is Inc. reports third quarter and nine months 2023 financial and operating results, with net revenues and net income representing increases of 378% and 1,018% respectively from the previous quarter

Retrieved on:

Friday, November 3, 2023

Fleet operational utilization of 98.5% for the three months ended September 30, 2023, as our vessels were mainly under time charter employment.

Key Points:

Fleet operational utilization of 98.5% for the three months ended September 30, 2023, as our vessels were mainly under time charter employment.
Voyage revenues of $10.1 million for the three months ended September 30, 2023, corresponding to a daily TCEi of $27,903.
378% increase in Net Revenues and 1,637% increase in EBITDA from the second quarter of 2023.
Net Income of $3.3 million for the three months ended September 30, 2023.

CDMO C3i Center Inc Located in Montreal, Canada Has Begun Manufacturing a Cell Therapy Product for Europe

Retrieved on:

Wednesday, September 20, 2023

Other Manufacturing, Research, Genetics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Oncology, CRISPR, Laboratory, Partnership, C3I, CDMO, EU

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.

Key Points:

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.
“We are proud of our team has worked very hard to be able to manufacture for EU clinical sites from our Montreal facility here in Canada.
C3i manufactures from process development all the way to phase 3 with the expected goal of commercial manufacturing launch end of 2024.
C3i has experience in autologous and allogeneic therapies using viral and non-viral methods as well as editing using CRISPR-based technologies.

C3is Inc. reports second quarter and six months 2023 financial and operating results

Retrieved on:

Friday, September 1, 2023

ATHENS, Greece, Sept. 01, 2023 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the second quarter and six months ended June 30, 2023.

Key Points:

ATHENS, Greece, Sept. 01, 2023 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the second quarter and six months ended June 30, 2023.
Voyage revenues of $4.9 million for the six months period ended June 30, 2023 corresponding to daily TCE1 of $12,145.
Our Company generated net income of $0.4 million for the six months period ended June 30, 2023, and net loss of $0.4 million for the three months ended June 30, 2023.
Voyage expenses and vessels’ operating expenses for the three months ended June 30, 2023 were $0.2 million and $0.8 million, respectively.

C3is Announces Agreement to Acquire One Aframax Oil Tanker, and Estimated Net Asset Value Premium at 370% Over Market Capitalization

Retrieved on:

Monday, July 17, 2023

United States v. Imperial Petroleum, Inc., Samsung, NAV, Hand, C3I, Acquisition, CISS, Cryptocurrency, Aframax

The vessel is currently trading in the spot market.

Key Points:

The vessel is currently trading in the spot market.
The transaction with Imperial Petroleum Inc., which is an affiliated company, was approved by the Company’s audit committee comprising of independent directors.
As of July 14, 2023, the Company’s management estimated C3is Inc’s Net Asset Value (“NAV”) to be $26.66 million, which represents approximately a 370% premium over its current market capitalization.
This NAV is based on recent charter-free vessel values and cash as of July 14, 2023, and does give effect to the acquisition of the Aframax oil tanker.

C3is Inc. Reports First Quarter 2023 Financial and Operating Results

Retrieved on:

Friday, June 23, 2023

Maintenance, C3I, Conference call, CISS, Bank statement, Calendar, United States v. Imperial Petroleum, Inc., Imperial, ET, PIN, Administration, Webcast, Transport, Conference, Airline, Shipbuilding

ATHENS, Greece, June 23, 2023 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk seaborne transportation services, announced today its unaudited financial and operating results for the first quarter ended March 31, 2023.

Key Points:

ATHENS, Greece, June 23, 2023 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk seaborne transportation services, announced today its unaudited financial and operating results for the first quarter ended March 31, 2023.
Successful spin-off of Imperial Petroleum Inc.’s two drybulk carriers to our newly listed company C3is Inc.; this was concluded on June 21, 2023.
Of the total calendar days in the first quarter of 2023, 163 or 90.6% were time charter days.
Voyage expenses and vessels’ operating expenses for the three months ended March 31, 2023 were $0.3 million and $1.0 million, respectively.

Imperial Petroleum Inc. Announces Completion of Spin-Off of C3is Inc.

Retrieved on:

Wednesday, June 21, 2023

C3I, United States v. Imperial Petroleum, Inc., Imperial, IMPP, Sale, Securities and Exchange Commission (Nigeria), Petroleum, Prospectus, Warrant, Security (finance)

ATHENS, Greece, June 21, 2023 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, today announced that it has completed the spin-off of its previously wholly-owned subsidiary, C3is Inc., the holding company for two drybulk carriers, effective June 21, 2023.

Key Points:

ATHENS, Greece, June 21, 2023 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, today announced that it has completed the spin-off of its previously wholly-owned subsidiary, C3is Inc., the holding company for two drybulk carriers, effective June 21, 2023.
Imperial Petroleum stockholders and warrantholders received one C3is common share for every eight shares of Imperial Petroleum’s common stock (“Imperial Petroleum common stock”) owned, or in the case of holders of Imperial Petroleum’s outstanding Warrants that they have the right to purchase pursuant to Warrants owned, at the close of business on June 13, 2023 (the “Record Date”).
Imperial Petroleum will retain an interest in C3is Inc. through its ownership of Series A Convertible Preferred Stock of C3is Inc., which was not distributed by Imperial Petroleum in the spin-off.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and become effective.

Imperial Petroleum Inc. Announces Record Date for Distribution of C3is Inc. Shares for Spin-Off of Two Drybulk Carriers

Retrieved on:

Friday, June 2, 2023

C3I, Date, United States v. Imperial Petroleum, Inc., Imperial, IMPP, Exchange, Securities and Exchange Commission (Nigeria), Sale, Prospectus, Warrant, Form, Security (finance)

Stockholders and warrantholders of the Company will receive one C3is common share for every eight shares of Imperial Petroleum’s common stock (“Imperial Petroleum common stock”) owned, or in the case of holders of Imperial Petroleum’s outstanding Warrants that they have the right to purchase pursuant to Warrants owned, at the close of business on June 13, 2023 (the “Record Date”).

Key Points:

Stockholders and warrantholders of the Company will receive one C3is common share for every eight shares of Imperial Petroleum’s common stock (“Imperial Petroleum common stock”) owned, or in the case of holders of Imperial Petroleum’s outstanding Warrants that they have the right to purchase pursuant to Warrants owned, at the close of business on June 13, 2023 (the “Record Date”).
The distribution is expected to be made on or about June 21, 2023 (the “Distribution Date”).
Shares of Imperial Petroleum common stock will trade with due bills from the Record Date through and including the Distribution Date.
Accordingly, shareholders and warrantholders of the Company as of the Record Date must continuously hold such shares of Imperial Petroleum common stock and Imperial Petroleum’s Warrants through and including the Distribution Date in order to receive shares of C3is Inc. in the spin-off.

Imperial Petroleum Inc. Announces Proposed Spin-Off of Two of Its Drybulk Carriers

Retrieved on:

Wednesday, April 12, 2023

Database, C3I, United States v. Imperial Petroleum, Inc., IMPP, Exchange, EDGAR, Sale, Prospectus, Form, SEC filing, Security (finance), Transport

C3is Inc., the newly formed subsidiary that will act as the holding company for the two drybulk carriers, has applied to have its common stock listed on the Nasdaq Capital Market.

Key Points:

C3is Inc., the newly formed subsidiary that will act as the holding company for the two drybulk carriers, has applied to have its common stock listed on the Nasdaq Capital Market.
There can be no assurance that the transaction will occur or, if one does occur, of its terms or timing.
The transaction will enable C3is Inc. to initially focus on the drybulk sector, while Imperial Petroleum Inc. gradually focuses on the tanker sector.
When available, a prospectus may be obtained by visiting the EDGAR database on the SEC's web site at www.sec.gov .

Avaya Named Leader Position in Inaugural Report from Aragon Research for Conversational AI (CAI) in the Intelligent Contact Center (ICC)

Retrieved on:

Monday, January 23, 2023

Avaya (NYSE:AVYA), a global leader in solutions to enhance and simplify communications and collaboration, today announced it has been named as a Leader in the inaugural report: The Aragon Research Globe™ for Conversational AI in the Intelligent Contact Center (ICC) 2023 by Aragon Research, Inc.

Key Points:

Avaya (NYSE:AVYA), a global leader in solutions to enhance and simplify communications and collaboration, today announced it has been named as a Leader in the inaugural report: The Aragon Research Globe™ for Conversational AI in the Intelligent Contact Center (ICC) 2023 by Aragon Research, Inc.
IVAs are also available to users independently for their issue resolution through self-service access delivering a seamless and simplified, omnichannel customer experience.
Avaya’s workflow automation is an available solution for conversational AI.
“Conversational AI in the contact center can greatly enhance both the customer and agent experience.

Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco

Retrieved on:

Wednesday, October 19, 2022

Oncology, Health, FDA, Clinical Trials, Research, Science, Biotechnology, Stomach, GPC3, Therapy, IND, GMP, Patient, Research, C3I, Cancer, Technology, Synthetic immunology, CEO, Safety, GUCY2C, Lonza, FDA, TAC, Pharmaceutical industry, Vaccine, Cain (band)

The advanced research and manufacturing space features an FDA-compliant GMP facility and will be staffed by Triumvira technical operations experts in cell therapy manufacturing, with plans for additional personnel in the coming years.

Key Points:

The advanced research and manufacturing space features an FDA-compliant GMP facility and will be staffed by Triumvira technical operations experts in cell therapy manufacturing, with plans for additional personnel in the coming years.
The South San Francisco facility is Triumviras second manufacturing location and is expected to provide supplemental manufacturing capacity to meet the demand for its ongoing clinical research studies.
Once operational, the South San Francisco facility will manufacture TAC01-HER2, which is currently in a Phase 1/2 trial for solid tumors, and manufacture additional candidates for subsequent clinical studies.
Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology.